A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

Acquired resistance to second generation BRAF inhibitors (BRAFis), like vemurafenib is limiting the benefits of long term targeted therapy for patients with malignant melanomas that harbor BRAF V600 mutations. Since many resistance mechanisms have been described, most of them causing a hyperactivati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EBioMedicine
Autori principali: Sinnberg, Tobias, Makino, Elena, Krueger, Marcel A., Velic, Ana, Macek, Boris, Rothbauer, Ulrich, Groll, Nicola, Pötz, Oliver, Czemmel, Stefan, Niessner, Heike, Meier, Friedegund, Ikenberg, Kristian, Garbe, Claus, Schittek, Birgit
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4919613/
https://ncbi.nlm.nih.gov/pubmed/27428425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2016.04.037
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi